Skip to content
 
  • 1. About the programme
  • 2. Announcement
  • 3. Create application

Coalition for Epidemic Preparedness Innovations (CEPI)

Deadline Announcement
17.10.2017
16:00 CEST
Closed
Platform technologies to enable rapid vaccine development for epidemic prone infections Choose
12.07.2017
16:00 CEST
Closed
Vaccine development against Lassa, MERS-CoV and Nipah viral diseases - Step 2 Choose
08.03.2017
16:00 CET
Closed
Vaccine development against Lassa, MERS-CoV and Nipah viral diseases Choose

Messages:

CEPI is an independent international non-profit coalition, with its secretariat hosted by the Norwegian Institute of Public Health in Oslo, Norway; in collaboration with the Wellcome Trust in London, England and the Department of Biotechnology in New Delhi, India.

Please note that the RCN application guidelines and requirements do not apply to this call of proposals. All required information is provided by CEPI in the announcement text and at the CEPI homepage.

Objectives:

Epidemics of emerging infectious diseases (EIDs), such as those identified in the World Health Organization (WHO) process termed “An R&D Blueprint for Action to Prevent Epidemics”, are a significant and growing threat to individual life, societies and general prosperity. They are pressing health security issues that the world faces today and in a world with increased urbanization, mobility and ecological change, their potential disruptive impact is increasing.

CEPI – the Coalition for Epidemic Preparedness Innovations – is a new international non-profit organization that was founded in August 2016 by the Government of Norway, the Bill & Melinda Gates Foundation, the Wellcome Trust, the World Economic Forum, and India’s Department of Biotechnology.

CEPI aims to foster, finance and facilitate vaccine development against epidemic infectious diseases in cases where market incentives alone do not achieve this. In order to achieve its goal, CEPI will initially focus on two priorities: moving development of new vaccines from late preclinical studies to proof-of-principle and safety in humans including small scale stockpiles of vaccine material for large scale efficacy testing in the event of epidemics; and support the development of vaccine technologies and manufacturing capabilities that can be deployed rapidly against outbreaks of known and unexpectedly emerging pathogens.

For more information on CEPI vision, mission, strategic objectives, policies and governance visit http://www.cepi.net/. You can directly access the preliminary business plan 2017-2021 here.

For objectives of the calls announced by CEPI, see under “Announcement” for  specific call.

Other websites